Hypercholesterolemia, Familial – Talk Bio

Actionable Insights Powered by AI

Merck’s Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

2 months ago talkbio0Tagged Administration of prophylactic statin, cholesterol, CORALreef, CORALreef AddOn, enlicitide, HeFH, Hypercholesterolemia, Familial, Hyperlipidemia, LDL-C, Merck, Oral Therapy, PCSK9 inhibitor

Merck; PCSK9 inhibitor; enlicitide; phase 3 trials; cholesterol; LDL-C; oral therapy; hyperlipidemia; familial hypercholesterolemia; CORALreef HeFH; CORALreef AddOn; statin therapy

NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations

12 months ago talkbio0Tagged Cardiovascular Diseases, CETP protein, human, Familial hypercholesterolemia - heterozygous, Heterozygote, High Density Lipoprotein Cholesterol, Hypercholesterolemia, Familial, Inhibitor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 Clinical Trials

NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease